Table of Contents

Articles

• You have access

  ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN

  Liyue Huang, Yi Wang and Scott Grimm

  Drug Metabolism and Disposition May 2006, 34 (5) 738-742; DOI: https://doi.org/10.1124/dmd.105.007534
• You have access

  INHIBITION OF OAT3-MEDIATED RENAL UPTAKE AS A MECHANISM FOR DRUG-DRUG INTERACTION BETWEEN FEXOFENADINE AND PROBENECID

  Harunobu Tahara, Hiroyuki Kusuhara, Kazuya Maeda, Hermann Koepsell, Eiichi Fuse and Yuichi Sugiyama

  Drug Metabolism and Disposition May 2006, 34 (5) 743-747; DOI: https://doi.org/10.1124/dmd.105.008375
• You have access

  N-GLUCURONIDATION OF THE PLATELET-DERIVED GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR 6,7-(DIMETHOXY-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)-(3-FLUORO-PHENYL)-AMINE BY HUMAN UDP-GLUCURONOSYLTRANSFERASES

  Z. Yan, G. W. Caldwell, D. Gauthier, G. C. Leo, J. Mei, C. Y. Ho, W. J. Jones, J. A. Masucci, R. W. Tuman, R. A. Galemmo and D. L. Johnson

  Drug Metabolism and Disposition May 2006, 34 (5) 748-755; DOI: https://doi.org/10.1124/dmd.106.009274
• You have access

  RIFAMPICIN INDUCTION OF CYP3A4 REQUIRES PREGNANE X RECEPTOR CROSS TALK WITH HEPATOCYTE NUCLEAR FACTOR 4α AND COACTIVATORS, AND SUPPRESSION OF SMALL HETERODIMER PARTNER GENE EXPRESSION

  Tiangang Li and John Y. L. Chiang

  Drug Metabolism and Disposition May 2006, 34 (5) 756-764; DOI: https://doi.org/10.1124/dmd.105.007575
• You have access

  PIMECROLIMUS: ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION IN HEALTHY VOLUNTEERS AFTER A SINGLE ORAL DOSE AND SUPPLEMENTARY INVESTIGATIONS IN VITRO

  Markus Zollinger, Felix Waldmeier, Stefan Hartmann, Gerhard Zenke, Alfred G. Zimmerlin, Ulrike Glaenzel, Jean-Pierre Baldeck, Alain Schweitzer, Stephane Berthier, Thomas Moenius and Maximilian A. Grassberger

  Drug Metabolism and Disposition May 2006, 34 (5) 765-774; DOI: https://doi.org/10.1124/dmd.105.007732
• You have access

  INFLUENCE OF ERYTHROMYCIN ON THE PHARMACOKINETICS OF XIMELAGATRAN MAY INVOLVE INHIBITION OF P-GLYCOPROTEIN-MEDIATED EXCRETION

  Ulf G. Eriksson, Hassan Dorani, Johan Karlsson, Holger Fritsch, Kurt-Jürgen Hoffmann, Lis Olsson, Troy C. Sarich, Ulrika Wall and Kajs-Marie Schützer

  Drug Metabolism and Disposition May 2006, 34 (5) 775-782; DOI: https://doi.org/10.1124/dmd.105.008607
• You have access

  DURATION OF PLECONARIL EFFECT ON CYTOCHROME P450 3A ACTIVITY IN HEALTHY ADULTS USING THE ORAL BIOMARKER MIDAZOLAM

  Joseph D. Ma, Anne N. Nafziger, Gerry Rhodes, Siyu Liu and Joseph S. Bertino

  Drug Metabolism and Disposition May 2006, 34 (5) 783-785; DOI: https://doi.org/10.1124/dmd.105.007831
• You have access

  IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES

  Jarkko Rautio, Joan E. Humphreys, Lindsey O. Webster, Anand Balakrishnan, John P. Keogh, Jeevan R. Kunta, Cosette J. Serabjit-Singh and Joseph W. Polli

  Drug Metabolism and Disposition May 2006, 34 (5) 786-792; DOI: https://doi.org/10.1124/dmd.105.008615
• You have access

  EFFECT OF P-GLYCOPROTEIN ON INTESTINAL ABSORPTION AND BRAIN PENETRATION OF ANTIALLERGIC AGENT BEPOTASTINE BESILATE

  Rikiya Ohashi, Yukari Kamikozawa, Mika Sugiura, Hajime Fukuda, Hikaru Yabuuchi and Ikumi Tamai

  Drug Metabolism and Disposition May 2006, 34 (5) 793-799; DOI: https://doi.org/10.1124/dmd.105.007559
• You have access

  THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR

  Daisuke Tenmizu, Kiyoshi Noguchi, Hidetaka Kamimura, Hisakazu Ohtani and Yasufumi Sawada

  Drug Metabolism and Disposition May 2006, 34 (5) 800-806; DOI: https://doi.org/10.1124/dmd.105.008722
• You have access

  BIOTRANSFORMATION OF CARBON-14-LABELED MURAGLITAZAR IN MALE MICE: INTERSPECIES DIFFERENCE IN METABOLIC PATHWAYS LEADING TO UNIQUE METABOLITES

  Wenying Li, Donglu Zhang, Lifei Wang, Hao Zhang, Peter T. Cheng, Duxi Zhang, Donald W. Everett and W. Griffith Humphreys

  Drug Metabolism and Disposition May 2006, 34 (5) 807-820; DOI: https://doi.org/10.1124/dmd.105.007856
• You have access

  OXIDATIVE METABOLISM OF THE ALKALOID RUTAECARPINE BY HUMAN CYTOCHROME P450

  Yune-Fang Ueng, Ming-Jaw Don, Woan-Ching Jan, Shu-Yun Wang, Li-Kang Ho and Chieh-Fu Chen

  Drug Metabolism and Disposition May 2006, 34 (5) 821-827; DOI: https://doi.org/10.1124/dmd.105.007849
• You have access

  DETECTION OF A NEW N-OXIDIZED METABOLITE OF FLUTAMIDE, N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]HYDROXYLAMINE, IN HUMAN LIVER MICROSOMES AND URINE OF PROSTATE CANCER PATIENTS

  Rika Goda, Daichi Nagai, Yuji Akiyama, Kiyohiro Nishikawa, Isao Ikemoto, Yoshio Aizawa, Kiyoshi Nagata and Yasushi Yamazoe

  Drug Metabolism and Disposition May 2006, 34 (5) 828-835; DOI: https://doi.org/10.1124/dmd.105.008623
• You have access

  EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO

  Yang Dai, Mary F. Hebert, Nina Isoherranen, Connie L. Davis, Christopher Marsh, Danny D. Shen and Kenneth E. Thummel

  Drug Metabolism and Disposition May 2006, 34 (5) 836-847; DOI: https://doi.org/10.1124/dmd.105.008680
• You have access

  THE ROLE OF CYP2A AND CYP2E1 IN THE METABOLISM OF 3-METHYLINDOLE IN PRIMARY CULTURED PORCINE HEPATOCYTES

  Michael A. Terner, W. James Gilmore, Yanping Lou and E. James Squires

  Drug Metabolism and Disposition May 2006, 34 (5) 848-854; DOI: https://doi.org/10.1124/dmd.105.008128
• You have access

  EVALUATION OF THE UTILITY OF BRAIN SLICE METHODS TO STUDY BRAIN PENETRATION

  Stacey Becker and Xingrong Liu

  Drug Metabolism and Disposition May 2006, 34 (5) 855-861; DOI: https://doi.org/10.1124/dmd.105.007914
• You have access

  OATP1B1, OATP1B3, AND MRP2 ARE INVOLVED IN HEPATOBILIARY TRANSPORT OF OLMESARTAN, A NOVEL ANGIOTENSIN II BLOCKER

  Rie Nakagomi-Hagihara, Daisuke Nakai, Kenji Kawai, Yasushi Yoshigae, Taro Tokui, Takaaki Abe and Toshihiko Ikeda

  Drug Metabolism and Disposition May 2006, 34 (5) 862-869; DOI: https://doi.org/10.1124/dmd.105.008888
• You have access

  GENE EXPRESSION IN HUMAN HEPATOCYTES IN SUSPENSION AFTER ISOLATION IS SIMILAR TO THE LIVER OF ORIGIN, IS NOT AFFECTED BY HEPATOCYTE COLD STORAGE AND CRYOPRESERVATION, BUT IS STRONGLY CHANGED AFTER HEPATOCYTE PLATING

  Lysiane Richert, Michael J. Liguori, Catherine Abadie, Bruno Heyd, Georges Mantion, Nermin Halkic and Jeffrey F. Waring

  Drug Metabolism and Disposition May 2006, 34 (5) 870-879; DOI: https://doi.org/10.1124/dmd.105.007708
• You have access

  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

  Mary F. Paine, Heather L. Hart, Shana S. Ludington, Robert L. Haining, Allan E. Rettie and Darryl C. Zeldin

  Drug Metabolism and Disposition May 2006, 34 (5) 880-886; DOI: https://doi.org/10.1124/dmd.105.008672
• You have access

  RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABA_A α5-SELECTIVE COMPOUND L-655,708

  John R. Atack, Andy Pike, Ashley Clarke, Susan M. Cook, Bindi Sohal, Ruth M. McKernan and Gerard R. Dawson

  Drug Metabolism and Disposition May 2006, 34 (5) 887-893; DOI: https://doi.org/10.1124/dmd.105.006973